Filing Flows › Comparisons › PFE vs AZN
Pfizer vs AstraZeneca: PFE and AZN compared
Pfizer is the larger company: $16.6B of revenue in its latest quarter (Q3 2026) against $16.2B for AstraZeneca (Q3 2026). AstraZeneca is growing faster (+7% against -0.4% a year earlier). AstraZeneca is more profitable, with an operating margin of 27.1% against 20.4%.
Where the money goes: PFE and AZN
Pfizer (PFE) · Q3 2026
Pfizer, Q3 2026: revenue $16.6B (-0.4% year over year), operating margin 20.4%, net earnings $3.3B, operating cash flow $5.4B. The chart follows the revenue to costs, profit and cash.
AstraZeneca (AZN) · Q3 2026
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart follows the revenue to costs, profit and cash.
| Pfizer (PFE) | AstraZeneca (AZN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $16.6B | $16.2B |
| Revenue growth, Y/Y | -0.4% | +7% |
| Gross margin | — | 81.8% |
| Operating margin | 20.4% | 27.1% |
| Net earnings | $3.3B | $3.1B |
| Net margin | 19.6% | 19.2% |
| Operating cash flow | $5.4B | $5.8B |
| Free cash flow | $4.8B | $5.1B |
| Market value | $169.0B | — |
| P/E | 42.0× | — |
| Analysts’ mean target | $30.11 | — |
Where the revenue comes from
AstraZeneca
- Oncology: $7.1B (44%)
- CVRM: $2.6B (16%)
- Farxiga: $1.6B (10%)
- Ultomiris: $1.4B (9%)
Questions
Which is bigger, Pfizer or AstraZeneca?
Pfizer is the larger company: $16.6B of revenue in its latest quarter (Q3 2026) against $16.2B for AstraZeneca (Q3 2026).
Is Pfizer or AstraZeneca growing faster?
AstraZeneca is growing faster (+7% against -0.4% a year earlier).
Which is more profitable, Pfizer or AstraZeneca?
AstraZeneca is more profitable, with an operating margin of 27.1% against 20.4%.
More: Pfizer earnings · how Pfizer makes money · AstraZeneca earnings · how AstraZeneca makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 6-K filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.